We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Adamis Pharmaceuticals

News List

Adamis Pharmaceuticals Resubmits Zimhi New Drug Application to FDA for the Treatment of Opioid Overdose drugs
May 20, 2021
Adamis Pharmaceuticals Corporation，today announced that the New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration (FDA) for Zimhi™, a naloxone injection product candidate intended for the treatment of opioid overdose.
Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet pharmafocusasia
January 02, 2019
Adamis Pharmaceuticals Corporation today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for....
Adamis Pharmaceuticals Adds Sublingual Erectile Dysfunction Product Candidate to its Pipeline pharmafocusasia
November 28, 2018
Adamis Pharmaceuticals Corporation announced today that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil......